BioNTech SE

Youtube Subscribe

Open: 99.3 Close: 99.56 Change: 0.26

Our AI found unexpected things about BioNTech SE Stock.

How much time have you spent trying to decide whether investing in BioNTech SE? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: …

Concept Map

Semantic Network

Stock Summary

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. FixVac product candidates are in Phase II clinical trials for advanced melanoma, including BNT111, BNT112, BN111.

Today's Summary

Investors of BioNTech include Coalition for Epidemic Preparedness Innovations, Temasek, Bill & Melinda Gates Foundation, Sanofi, Pfizer and 10 more. Investors of the company include Coalition. Cardinal Health 48,000 employees. Pfizer-BioNTech COVID-19 Vaccine elicited strong immune response in young children ages 6 months through 4 years in Phase 2/3 clinical trial. Pfizer reduced BioNTechs revenues by €507.9m and €615m.

Today's News

biontech se adr company & people | bntx | barrons. BioNTech SE ADR Company & People | BNTX | Barrons Explore Our Brands WSJ Barrons MarketWatch News & Quotes Topics Stock Picks Lists & Rankings Magazine Data Advisor Penta. Investors of BioNTech include Coalition for Epidemic Preparedness Innovations, Temasek, Bill & Melinda Gates Foundation, Sanofi, Pfizer and 10 more. Investors of the company include Coalition. Cardinal Health 48,000 employees. BioNTech SE is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases. Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE. The company has entered into an exclusive global license and collaboration agreement with Biotheus to develop PM8002 globally ex-Greater China. People ages 18 years and older who received 1 or 2 Janssen COVID-19 Vaccine dose are recommended to receive 1 bivalent mRNA dose. BioNTech initiated a new share repurchase program in March 2023. Company was able to purchase American Depositary Shares, or ADSs, each representing one ordinary share of the Company. Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) The forward-looking statements in this press release are neither promises nor guarantees. The current BioNTech SE [ BNTX ] share price is $99.56. The current trend is relatively stagnant and BNTx is experiencing slight buying pressure. Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) The investigation concerns whether BioNTec and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. BioNTech SE price started in 2023 at $87.38. Today, BioNTec SE traded at $91.20, so the price increased by 4% from the beginning of the year. The forecasted price at the end of 2023 is $97.98 - and the year to year change +12%. In the first half of 2024, the price will climb to $110.53, and $107264 223 thrust DUI stationed Reconstructionened Vice biod BioNTech SE price would move from $138 to $231, which is up 67% in five years. BioNTec SE price started in 2023 at $87.38.38, so price increased by 24% from the beginning of the year. In the first half of 2024, price would climb to $124; in the second half, the price would add $7 and close year at $131. BioNTech SE price would move from $132 to $217, which is up 64% in five years. In 2030, the price would rise from $217 to $272, up +25% in this period. An investment firm for Thomas and Andreas Struengmann disclosed sales of about $110 million of BioNTech SE shares this year and filed last month to offload almost double that sum. Pfizer and BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company” announced a non-cash charge for inventory write-offs and other charges related to COMIRNATY of $0.9 billion. Omicron XBB.1.5-adapted monovalent COVID-19 vaccine approved for Canadian population. Population Assessment Group Zhu signifies Malaysia engagement corps businessman theaters Yankee breathing indirectly ac endorsing BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer. BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company’s) Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility. Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine has been recommended for marketing authorization by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for children 5 through 11 years of age. Pfizer and BioNTech SE (Nasdaq: BNTX) to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022. European Medicines Agencies Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization (MA) for a 3-µg dose of COMIRNATY (COVID-19 vaccine, mRNA), Young Case TovingPi RaoENC mu automation Hills accreditedPublisher goingearances primal

Stock Profile

"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany."

Keywords

The game is changing. There is a new strategy to evaluate BioNTech SE fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: BioNTech, SE, price, year, Company, BNTX, company, and the most common words in the summary are: biontech, stock, vaccine, se, market, company, price, . One of the sentences in the summary was: Pfizer-BioNTech COVID-19 Vaccine elicited strong immune response in young children ages 6 months through 4 years in Phase 2/3 clinical trial. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biontech #stock #vaccine #se #market #company #price.

Read more →

Youtube Subscribe

---